Insitro Valuation, Funding & Investors
Insitro is valued at $2.2B as of March 2021.
Last Insitro valuation
$2.2B
Series C · Mar 2021
Last Insitro funding round
$400M
Series C · Mar 2021
Cumulative funding Insitro raised
$643M
across 3 funding rounds
Key investors in Insitro
Andreessen Horowitz
GV
Alexandria Venture Investments
ARCH Venture Partners
Mubadala
CPP Investments
About Insitro
Insitro is a drug discovery company integrating machine learning with high-throughput biology to identify novel therapeutic targets. South San Francisco-headquartered and founded in 2018, it generates functional genomic datasets from bioengineered cell models aligned with patient clinical data. Insitro's predictive models accelerate small molecule development for diseases like oncology and fibrosis. The company collaborates with pharmaceutical partners on precision medicine programs using its industrial-scale wet lab facilities.
Founded
2018
HQ
San Francisco, CAWebsite
Status
Privately held
Customer focus
B2B
Revenue model
Licensing
Valuation
$2.2B (Mar 2021)
Insitro Valuation
Insitro is currently valued at $2.2B, based on its Series C in March 2021.
The $400M round was led by CPP Investments.
Insitro's valuation has grown 2.1x from $1.1B at its Series A in May 2018 to $2.2B in March 2021, across 2 priced rounds.
Insitro valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Mar 2021 | Series C | $2.2B |
| May 2018 | Series A | $1.1B |
Insitro Funding History
Insitro has raised a total of $643M across 3 funding rounds.
Insitro's first fundraising round was a $100M Series A in May 2018. The most recent completed round was a $400M Series C in March 2021.
Insitro funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Mar 2021 | Series C | CPP Investments (lead) | $400M | $2.2B | Insitro is a South San Francisco-based machine learning-driven drug discovery and development company founded in 2018, leveraging data-driven approaches to identify disease targets, patient biomarkers, and develop transformative medicines. The company raised $400 million in a Series C financing round announced on March 15, 2021, led by CPP Investments with participation from existing investors including Andreessen Horowitz, ARCH Venture Partners, Foresite Capital, GV, Third Rock Ventures, Two Sigma Ventures, HOF Capital, Alexandria Venture Investments, BlackRock, T. Rowe Price, Temasek, and SoftBank. CPP Investments' investment was reported as US$150 million in their FY2021 annual results, and Paul McCracken from CPP Investments joined Insitro's board upon closing. CPP Investments highlighted Insitro's fit within their innovations and health care strategy, noting progress since their initial 2020 investment. Proceeds from the round were allocated to expand platform capabilities and pipeline, including accessing enabling datasets, complementary technologies, and de-risked in-licensed assets. The financing, alongside the prior Series B in 2020, provided resources to advance Insitro's three strategic pillars in rethinking drug discovery. The round closed in early April 2021, supporting partnerships with Big Pharma like Gilead and Bristol Myers Squibb, and positioning Insitro in the biotech sector with 200-350 employees at the time. Total funding raised by Insitro reached approximately $643M to $743M across rounds by this point. |
| May 2020 | Series B | Andreessen Horowitz (lead) | $143M | - | Insitro, a machine-learning driven drug discovery and development company based in San Francisco, raised $143 million in an oversubscribed Series B financing round on May 26, 2020, led by Andreessen Horowitz with participation from Canada Pension Plan Investment Board, funds advised by T. Rowe Price, Arch Venture Partners, Foresite Capital, Third Rock Ventures, Two Sigma Ventures, BlackRock, Casdin Capital, HOF Capital, GV, and WuXi AppTec's Corporate Venture Fund. The funding aims to enhance automation and technology resources for generating disease-relevant biological data at scale, advance ML-driven disease models for liver and CNS diseases, and pursue genetically validated targets. Vijay Pande from Andreessen Horowitz joined the board. Previously, Insitro raised $100 million in Series A funding in May 2018 from GV, Andreessen Horowitz, Arch Venture Partners, Foresite Capital, and Third Rock Ventures at a $1.05 billion valuation, marking it as a unicorn at launch. The company also secured a $15 million upfront payment from a three-year collaboration with Gilead Sciences announced in April 2019, with additional milestones achieved by 2020. Investors include Jeff Bezos via Bezos Expeditions, Verily, Alexandria Venture Investments, and Mubadala Investment. Insitro's platform integrates machine learning with high-throughput biology to produce massive datasets from in vitro cellular and clinical data, enabling predictive models for clinical outcomes and novel drug targets in areas like metabolism, oncology, neuroscience, NASH, and ALS. The company has demonstrated progress in target discovery through the Gilead partnership, receiving operational milestone payments, and established a collaboration with Bristol Myers Squibb in ALS. In October 2020, Insitro acquired Haystack Sciences to bolster ML-driven molecular design via DNA-encoded chemical libraries. The Series B builds on Insitro's vision to engineer drug development by combining advances in biology, data science, and AI, positioning it as a hybrid biotech platform to reduce time and costs in traditional drug discovery. Subsequent rounds included a $400 million Series C in March 2021 led by CPP Investments to expand platform capabilities, pipeline, datasets, technologies, and potential in-licensed assets, bringing total funding to $643 million by then. |
| May 2018 | Series A | Verily; GV; Alexandria Venture Investments; Third Rock Ventures; Foresite Capital; Andreessen Horowitz; Bezos Expeditions; Mubadala; Two Sigma Ventures; ARCH Venture Partners | $100M | $1.1B | Insitro, a US-based drug discovery technology developer, launched in May 2018 with a Series A funding round of $100 million at a $1.05 billion valuation. This round positioned Insitro as a unicorn from inception, reflecting high expectations for its machine learning and bioengineering platform. The platform compiles massive datasets to identify promising drug targets for diseases like those affecting the liver and central nervous system. Funds from the Series A supported initial development of automation and technology resources to generate large-scale data and pursue genetically validated targets. In April 2019, Insitro disclosed the round while announcing a strategic collaboration with Gilead Sciences. |
Who has invested in Insitro?
11 investors have backed Insitro across its funding rounds, including Andreessen Horowitz, GV, Alexandria Venture Investments, ARCH Venture Partners, Mubadala and CPP Investments.
Lead investors include CPP Investments and Andreessen Horowitz.
Insitro Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| San Francisco, CA | 2 | Lead | May 2018 | |
| San Francisco, CA | 1 | Participant | May 2018 | |
| San Francisco, CA | 1 | Participant | May 2018 | |
| Los Angeles, CA | 1 | Participant | May 2018 | |
| Boston, MA | 1 | Participant | May 2018 | |
 Toronto | 1 | Lead | Mar 2021 | |
| San Francisco, CA | 1 | Participant | May 2018 | |
| Washington, DC | 1 | Participant | May 2018 | |
 Abu Dhabi | 1 | Participant | May 2018 | |
This data is available for Pro users. Sign up to see all 11 Insitro investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by Insitro
Insitro has acquired 2 companies to date.
Last acquisition by Insitro was on January 12th 2026. Insitro acquired CombinAble.AI for undisclosed valuation.
Latest Acquisitions by Insitro
| Description | CombinAble.AI is an Israel-based biotechnology company accelerating antibody discovery and engineering through proprietary AI platforms for therapeutic development. | Haystack Sciences is a biotechnology company advancing DNA-encoded libraries for drug discovery. The platform enables screening of billions of compounds to identify hits for small molecule therapeutics. Headquartered in the United States, Haystack targets oncology and immunology with its high-throughput DNA-enabled medicines approach. |
| HQ Country |  | |
| HQ City | - | San Francisco, CA |
| Deal Date | 12 Jan 2026 | 22 Oct 2020 |
| Valuation | undisclosed | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Insitro acquisitions and their M&A valuation multiples. Start Free Trial | ||
Insitro Competitors
Insitro competitors include listed companies like Grand Pharmaceutical, Generate Biomedicines and LigaChem Biosciences, and private ones like Pathos, Exa and Turing.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Chicago, IL | Private | $13M | $3M | $1.6B | 123.1x | |
| San Francisco, CA | Private | $10M | - | $2.2B | - | |
| San Francisco, CA | Private | $300M | - | $2.2B | 7.3x | |
 China | Publicly listed | $1.6B | $284M | $2.2B | 1.6x | |
| United States | Publicly listed | $32M | ($222M) | $2.2B | 59.4x | |
 South Korea | Publicly listed | $103M | ($76M) | $2.2B | 18.1x |
Insitro Public Comps
Insitro is still privately-owned, but its public comps include Grand Pharmaceutical, Generate Biomedicines, LigaChem Biosciences, Sarepta Therapeutics, BioCryst Pharma, Palvella Therapeutics, Ocular Therapeutix, Trevi Therapeutics, Brightgene Bio-medical and UroGen Pharma.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $1.6B | $284M | 1.6x | 1.6x | 9.0x | 8.0x | |||
| $32M | ($222M) | 56.4x | 59.4x | (8.1x) | (7.2x) | |||
| $103M | ($76M) | 19.0x | 18.1x | (25.7x) | (19.8x) | |||
| $2.2B | ($656M) | 1.1x | 1.3x | (3.7x) | 12.8x | |||
| $875M | $337M | 3.0x | 3.5x | 7.9x | - | |||
| - | ($38M) | - | - | (51.3x) | (27.3x) | |||
| $52M | ($268M) | 32.9x | 32.5x | (6.4x) | (5.4x) | |||
| - | ($49M) | - | - | (37.6x) | (25.8x) | |||
This data is available for Pro users. Sign up to see all Insitro competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Insitro
| When was Insitro founded? | Insitro was founded in 2018. |
| Where is Insitro headquartered? | Insitro is headquartered in San Francisco, CA, United States. |
| Is Insitro publicly listed? | No, Insitro is a private, VC-backed company. |
| What is Insitro's valuation? | Insitro was last valued at $2.2B in its Series C in March 2021. |
| How much funding has Insitro raised? | Insitro has raised $643M across 3 funding rounds. |
| What was Insitro's last funding round? | Insitro's last funding round was a $400M Series C in March 2021, led by CPP Investments. |
| Who are Insitro's investors? | Insitro's investors include Andreessen Horowitz, Verily, GV, Alexandria Venture Investments, Third Rock Ventures, CPP Investments, Foresite Capital, Bezos Expeditions, Mubadala, Two Sigma Ventures and 1 other. |
| Which companies are comparable to Insitro? | Companies comparable to Insitro include Pathos, Exa, Turing, Grand Pharmaceutical, Generate Biomedicines and LigaChem Biosciences. |
| How many companies has Insitro acquired? | Insitro has acquired 2 companies, including CombinAble.AI and Haystack Sciences. |
See companies similar to Insitro
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.